Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Phase 2 N=27 Prescription Opioid Effects in Abusers Versus Non-Abusers
Opioid-Related Disorders · Substance-Related Disorders
Primary: Breakpoint — 25; 400; 1400; 850 Mouse Clicks
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
N/A N=843 Personalized Health Assessment Related to Medications (Project PHARM)
Feedback, Psychological · Clinical Trial · Substance Abuse
Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03
N/A N=1,525 The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances
Economics · Fraud · Delivery of Health Care
Primary: 30-day Equivalent Prescribing of Schedule II Controlled Substances — 461.1; 450.0 30-day equivalent prescription fills
N/A N=235 Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention
Prescription Drug Abuse (Not Dependent) · Intentional Misuse
Primary: Frequency of Prescription Stimulant Diversion — .25; .41; .18; .30 Mean number of times diverted — p=.499
Phase 1 N=25 Effects of Commonly Used Medications on Mood and Choice
Healthy
Primary: Participant Subjective Ratings of Drug Liking (Peak Change) — 1.00; -0.11; 0.88; 0.33 score on a scale
N/A N=201 Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
Aging · Benzodiazepine Sedative Adverse Reaction · Anticholinergic Adverse Reaction
Primary: Change in Inappropriate Prescribing by Study Arm: Descriptive Comparison Across Study Arms — 35.2; 33; 35.6; 40.6 percentage of patients
N/A N=299 Primary Care Intervention to Reduce Prescription Opioid Overdoses
Pain · Drug Overdose · Opioid Use Disorders
Primary: Overdose Risk Behaviors — 1.31; 1.21; 1.45; 1.25 score on a scale
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
N/A N=851 Behavioral Insights to Encourage Judicious Prescribing of Opioids
Substance-Related Disorders
Primary: Average Change Over Time in Dispensed Narcotics — 347.65; 350.09; 288.36; 318.60 Morphine milligram equivalents — p=<0.05
Phase 2 N=120 Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription
Surgery
Primary: Number of Oxycodone Tablets Used Day 1 — 1.0; 1.0 Oxycodone Tablets — p=.87
N/A N=14,442 A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease
Alzheimer Disease
Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76
Phase 4 N=63 Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Abuse Potential
Primary: Drug Liking Visual Analog Scale (VAS) — 56.4; 84.9; 59.6; 64.6 score on a scale
Phase 1 N=31 Staccato Alprazolam Abuse Liability
Abuse Liability of Staccato Alprazolam
Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale
Phase 1 N=80 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Nondependent Opioid Abuse, Episodic
Primary: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours — 88.3; 100.3; 124.7 hrs*mm — p=<0.0001
N/A N=160 Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension
Cardiovascular Diseases · Heart Diseases · Hypertension
Primary: Behaviors Risk Score — 17.9; 16.6; 16.4; 12.6 units on a scale — p=0.035
Phase 2 N=17 Medication Development for Opioid and Alcohol Abuse
Opioid-use Disorder · Alcohol Use Disorder
Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
Phase 2 N=44 Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related Disorders
Primary: Emax - Maximum Drug Liking — 54.5; 75.0; 72.1; 75.6 score on a scale
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
N/A N=1,146 NUDGE-EHR Replication Trial at Mass General Brigham
Aging · Benzodiazepine Sedative Adverse Reaction · Anticholinergic Adverse Reaction
Primary: Change in Inappropriate Prescribing — 106; 145; 122 Participants — p=0.002
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 1 N=12 A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route
Pain · Nausea · Vomiting
Primary: Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase — 85.0; 42.0; 75.5; 94.0 units on a scale
Phase 2 N=32 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
N/A N=112 Co-Use of Opioid Medications and Alcohol Prevention Study
Alcohol Drinking · Opioid Use
Primary: Alcohol Use Reductions — 11; 12; 1; 1 Participants
N/A N=149 Medication Education for Dosing Safety
Pain · Fever
Primary: Number of Participants Reporting Safe Dosing at 48-72 Hours — 28; 25 Participants
N/A N=49 Consensus-based Algorithms to Address Opioid Misuse Behaviors Among Individuals Prescribed Long-term Opioid Therapy
Opioid Misuse · Chronic Pain
Primary: Feasibility of Algorithms — 7; 13 Participants